

REVIEW

Open Access



Novel drugs that target the metabolic reprogramming in renal cell cancer

Johannes C. van der Mijn^{1,2,3*}, David J. Panka¹, Andrew K. Geissler¹, Henk. M. Verheul² and James W. Mier¹

Abstract

Molecular profiling studies of tumor tissue from patients with clear cell renal cell cancer (ccRCC) have revealed extensive metabolic reprogramming in this disease. Associations were found between metabolic reprogramming, histopathologic Fuhrman grade, and overall survival of patients. Large-scale genomics, proteomics, and metabolomic analyses have been performed to identify the molecular players in this process. Genes involved in glycolysis, the pentose phosphate pathway, glutamine metabolism, and lipogenesis were found to be upregulated in renal cell cancer (RCC) specimens as compared to normal tissue. Preclinical research indicates that mutations in VHL, FBP1, and the PI3K-AKT-mTOR pathway drives aerobic glycolysis through transcriptional activation of the hypoxia-inducible factors (HIF). Mechanistic studies revealed glutamine as an important source for de novo fatty acid synthesis through reductive carboxylation. Amplification of MYC drives reductive carboxylation. In this review, we present a detailed overview of the metabolic changes in RCC in conjunction with potential novel therapeutics. We discuss preclinical studies that have investigated targeted agents that interfere with various aspects of tumor cell metabolism and emphasize their impact specifically on glycolysis, lipogenesis, and tumor growth. Furthermore, we describe a number of phase 1 and 2 clinical trials that have been conducted with these agents.

Keywords: Warburg, Renal cell cancer, HIF, MYC, Glutamine

Background

Renal cell cancer (RCC) is an aggressive type of cancer that arises from the proximal renal tubular epithelium of the kidneys. It occurs as sporadic cancer as well as part of hereditary cancer syndromes. RCC accounts for ~80 % of all sporadic kidney cancers and has displayed a rising incidence over the last decades [1, 2]. Different histological subvariants of RCC can be recognized with “clear cell renal cell cancer” representing 88 % in contemporary pathological series [3]. Papillary and chromophobe cancer are other subtypes of RCC. Identification of the von Hippel-Lindau (VHL) gene, as most frequently deleted gene in RCC cells, accelerated development of vascular endothelial growth factor (VEGF)-targeted therapy for treatment of the disease. Silencing of VHL, resulting in accumulation of the hypoxia-inducible factor (HIF) transcription factors, induces elevated levels of VEGF in

tumor cells. Upregulation of VEGF has been associated with the rich vascularization of tumors that is typically seen in tumors of patients with RCC. Five VEGF-targeted drugs (sunitinib, pazopanib, sorafenib, axitinib, and bevacizumab) are registered as therapeutic agent for treatment of RCC. Despite an increasing number of therapeutic options, the prognosis of patients with advanced RCC remains dismal. Locally advanced or metastatic RCC cannot be cured with current treatments.

A large retrospective cohort study was performed by “The Cancer Genome Atlas” (TCGA) consortium among patients with RCC [4]. Upregulation of genes involved in glycolysis was found, while genes, known to play a role in the tricarboxylic acid (TCA) cycle, were found to be downregulated [4, 5]. The altered pattern in glucose metabolism in tumors has first been described by the German physiologist Otto Warburg as aerobic glycolysis [6]. This phenomenon, nowadays frequently referred to as “the Warburg effect,” has been found in an important subset of the patients with RCC and was associated with a poor prognostic outcome. In this review, we will provide a detailed overview of the genetic changes

* Correspondence: j.vandermijn@vumc.nl

¹Department of Hematology/Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Ave, Boston, MA 02215, USA

²Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

Full list of author information is available at the end of the article

that cause the Warburg effect, in conjunction with therapeutic agents that may interfere with this process.

Besides changes in glucose metabolism, numerous other metabolic changes have been detected in RCC specimens and include amino acid and lipid metabolism. Arginine, tryptophan, and glutamine are examples of amino acids with altered dynamics. Genetic defects in cancer cells lead to increased import of these amino acids from the extracellular space. Furthermore, upregulation was found of genes involved in de novo fatty acid synthesis (lipogenesis) by TCGA [4]. Upregulation of lipogenesis and intracellular storage of lipid droplets causes the typical histopathological “clear cell” phenotype in RCC (clear cell renal cell cancer (ccRCC)) [7]. Preclinical research indicated that increased lipid storage also alleviates endoplasmic reticulum (ER) stress [7]. Dependence on extracellular amino acid supplies and upregulation of lipogenesis were shown to create vulnerabilities that can potentially be exploited by therapeutic agents such as Peg-Arg-1 and 5-(tetradecyloxy)-2-furoic acid (TOFA) [8, 9].

Tumors with nutrient metabolism reprogramming carry a poor prognostic outcome, which suggests potential of this process as a drug target. The metabolic changes are a common molecular feature of advanced RCC tumors. The frequency of genetic changes is of importance for the selection of potential therapeutic targets. The fundamental idea of anticancer drugs is to target molecules and cellular processes that are essential for tumor cell survival and less important to non-proliferating normal cells. Selective pressure due to survival advantage of certain genetic defects may give enrichment of those alterations in tumors. A higher frequency of these genetic defects in patient series also creates a larger platform for drugs that specifically interfere with it. The VHL-HIF-VEGF axis as most frequently activated pathway in RCC and therapeutic target is here an exemplary case. The frequency of the metabolic reprogramming may render RCC a suitable disease for the investigation of potential novel therapeutic agents that target tumor metabolism.

Part I. Metabolic pathways with altered activity in human RCC


Results from molecular profiling studies of human RCC specimens

Frequent mutation of components in the PI3K-AKT-mTOR signaling pathway was found in early genetic sequencing studies [10]. TCGA consortium performed an integrated genome, transcriptome, proteome, and methylome analysis of tumor specimens from 400 patients with ccRCC [4]. Mutation of PTEN, TSC1/2, and PIK3CA, which were detected in the early sequencing studies and all reside in the PI3K-AKT-mTOR pathway, could be

confirmed by TCGA in 28 % of the tissues. Furthermore, they were the first to report comprehensive information on the RNA expression levels of various genes involved in metabolism (see Fig. 1 for an overview of the alterations). Fatty acid synthesis (FASN) and the glutamine- (SLC1A5) and lactate transporter genes (MCT1 and MCT4) were frequently found to be upregulated in aggressive tumors. Hexokinase, phosphofructokinase (PFK), pyruvate dehydrogenase kinase (PDK), alpha-enolase (ENO1), and lactate dehydrogenase (LDH-A) are critical enzymes in the glycolytic reactions and also examples of upregulated genes in TCGA RNA expression analysis [4]. Overexpression of LDH-A, MCT4, and ENO1 has been confirmed in independent patient cohorts [11–14]. The pentose phosphate pathway (PPP) branches from the glycolytic pathway and also appeared to be activated. Glucose-6-phosphate dehydrogenase (G6PD) and transketolase (TKT) are bidirectional and rate-limiting enzymes in the PPP with elevated expression levels [4]. Aconitase 2 (ACO2), α -ketoglutarate dehydrogenase (OGDH), and succinate dehydrogenase (SDHB) are examples of enzymes in the TCA cycle with diminished expression in TCGA RNA expression analysis [4]. Reduced AMP-activated kinase (AMPK) and increased acetyl-CoA carboxylase (ACC) protein levels were observed with a notable independent association with poor overall survival of patients [4].

Gene expression profiles have also been analyzed through mass spectrometry [15]. This analysis revealed upregulation of protein levels of glyceraldehyde-phosphate-dehydrogenase (GAPDH), phosphoglycerate kinase (PGK1), ENO2, pyruvate kinase (PKM2), and LDH-A in RCC specimens ($n = 40$) as compared to normal tissue [15]. The TCA cycle enzymes pyruvate carboxylase (PC), SDHA, and SDHB were downregulated. The same pattern was observed for enzymes involved in the β -oxidation of fatty acids like hydroxylacyl-CoA dehydrogenase (HADH), short-chain enoyl-coA hydratase (SCEH), very long chain acyl-coenzyme A dehydrogenase (VLCAD), acetyl-coA acetyltransferase (ACAT1), and medium-chain acyl-coA dehydrogenase (MCAD). No significant differences in isocitrate dehydrogenase (IDH1/2) protein levels were observed between RCC and normal kidney tissues.

Regulation of glycolysis, amino acid metabolism, and lipogenesis has also been subject of two metabolomics studies performed on a single cohort of 138 patients with RCC [16, 17]. Real-time flux analysis provides superior information on upregulation of metabolic pathways as compared to the snapshot analysis performed in these two studies. Both up- and downregulation of individual metabolites can be indicative of increased metabolism, which hampers the interpretation of the results. Both Wettersten et al. and Hakimi et al. showed



increased glucose, glu-6-P, fru-6-P, and lactate levels in RCC tissue as compared to healthy control tissue with notable association with the histopathologic nuclear grading system according to Fuhrman. Lower levels of TCA intermediates malate and fumarate were detected, while citrate and succinate were elevated. The levels of free fatty acids, glutamine, glutathione (GSH), and glutathione disulfide (GSSG) were increased and displayed an association with Fuhrman grade [16, 17]. Elevations of numerous consecutive metabolites (glucose, glu-6-p, fru-6-p, 6-PG) and their corresponding enzymes (HK, G6PD) do suggest upregulation of the first steps of the glycolytic pathway.

Certain aspects of these metabolomics studies require further investigation. Integrated analyses of transcriptomics and metabolomics showed a lack of linearity. For example, a remarkable depletion of a number of glycolytic metabolites (3-PG, 2-PG, and PEP) was noted along with overexpression of their corresponding glycolytic enzymes (PGK1, ENO2, PKM; see also Fig. 1) [17]. These results may reflect the fact that metabolic flux patterns do not always follow canonical flow but link and shunt into neighboring pathways. They indicate that more dynamic flux analyses are required to improve our understanding of this aspect of cancer biology. Moreover, they stress the importance of functional interference studies for development of therapeutics. The association between metabolites and Fuhrman grade does indicate that

the natural disease course in patients with RCC, as reflected by increasing Fuhrman grade, is accompanied by progressive metabolic reprogramming.

The most recent metabolomics study marked shunting of glucose in the PPP and production of glutathione as poor prognostic features [17]. This conclusion is in agreement with the conclusion of the analysis by TCGA. Elevated levels of glucose corresponded to increases in the PPP intermediate 6-phosphogluconate (6-PG), supporting elevated PPP-flux. In addition, higher levels of GSH were detected along with its precursor glutamine in the poor prognosis subgroup. GSH buffers reactive oxygen species by serving as electron donor, which is accompanied by oxidation to GSSG. GSSG can be converted back to GSH by glutathione reductase. This reaction requires NADPH, which is an important product of G6PD activity in the PPP. Through this role, the PPP is thought to contribute to an improved redox state of RCC cells. High levels of GSH coincided with hotspot mutations in the gene encoding NRF2 and its negative regulator KEAP1. NRF2 is known to drive expression of multiple components of antioxidant defense system, including the GSH-producing enzymes [18]. Late stage RCC tumors may therefore increase the capacity to buffer oxidative stress, not only through upregulation of the PPP but also through activation of the NRF2 antioxidant response pathway.

Molecular drivers of the metabolic reprogramming in RCC

Genome-wide association studies suggest a role of chromosome 3p loss in the metabolic reprogramming in RCC. The VHL, along with the metabolic regulator pyruvate dehydrogenase B (PDH-B), resides on a 50-Mb stretch of DNA on this chromosome. A large chromosomal copy number analysis indicated that this region is the most frequently deleted region in RCC (91 % of the samples) [19]. Loss of chromosome 3p and VHL correlated with divergence of metabolic gene expression in a large meta-analysis [5]. PBRM1, SETD2, and BAP1 are chromatin-modifying genes also located at chromosome 3p, but until now, no role has been identified for these genes in regulation of metabolism.

Transcriptional activity of the HIF may be the driving force behind the Warburg effect in RCC. Two isoforms of HIF exist, with the majority of RCC tumors (61 %) expressing both isoforms [20]. Loss of VHL results in normoxic HIF stabilization and enhances transcription of target genes. HIF1 was found to drive expression of GLUT1, PGK1, LDH-A, PDK1, and HK2 in transgenic mice with differential HIF1/HIF2 expression [21]. Suppression of oxidative phosphorylation in the TCA cycle was also found to be mediated by HIF1, through its target gene *Dec1* and the transcriptional coactivator PGC-1 α [22]. While evidence supports an important role of HIF1 in promoting aerobic glycolysis [21], it has also been shown to act as a tumor suppressor in preclinical RCC models [23]. Indeed, some tumors appear to have lost the HIF1 locus on chromosome 14q23, but surprisingly, no correlation was found between this deletion and HIF1A protein expression in RCC samples [19]. Future research will have to show whether correlations exist between HIF1 and/or HIF2 and the metabolic phenotype of RCC tumors.

Although loss of VHL may be a crucial event in RCC tumorigenesis, isolated loss does not elicit the characteristic HIF-transcriptional signatures [24]. Loss of fructose-1,6-bisphosphatase 1 (FBP1) on chromosome 9q22 is another unique feature of RCC [19]. Examination of its expression in 600 human RCC specimens revealed depletion in almost 100 % of the tumors as compared to normal kidney tissue [25]. Manipulation of FBP1 in normal kidney cells recapitulated numerous features of ccRCC tumors with markedly elevated glucose consumption and increased production of lactate, GSH, and NADPH [25]. Under physiological conditions, FBP1 opposes glycolysis and supports gluconeogenesis through production of Fru-6-p from Fru-1,6-P2 (see Fig. 1). In addition to this role in gluconeogenesis, the molecule was found to interact directly with HIF1 and HIF2, restraining their transcriptional activity [25]. Loss of FBP1 was associated with expression of several HIF-target genes, including PDK1, LDH-A, and GLUT1

[25]. Combined loss of VHL and FBP1 may therefore be an essential step in the development of the aerobic glycolysis phenotype in RCC.

The previously described molecular profiling studies revealed high levels of glutamine and free fatty acids in RCC specimens. Preclinical research indicates that these upregulated levels may be related to each other. In addition to its function as GSH precursor, glutamine can be transformed into α -ketoglutarate and oxidized in the TCA cycle. OGDH, which is the enzyme responsible for metabolism of α -ketoglutarate in the TCA cycle, was frequently found to be downregulated in RCC cells. IDH diverts α -ketoglutarate in the opposite direction in the TCA cycle through a process called “reductive carboxylation” [26]. Glutamine is transformed into citrate and acetyl-CoA in this pathway (Fig. 1) [27]. ACC and FASN mediate subsequent formation of fatty acids. The elevated levels of the ACC and FASN gene products as well as glutamine, citrate, and fatty acids in RCC specimens support potential activation of this pathway. High levels of fatty acids were measured in RCC cells, along with downregulation of the enzymes involved in β -oxidation [15]. Histological analysis showed intracellular storage of fatty acids as “lipid droplets” near the ER [7]. Storage of lipids relied on the HIF2-dependent gene *perilipin 2* (PLIN2) and suppressed cytotoxic ER stress through a reduction of protein synthesis [7]. This information shows that tumor cells may upregulate glutamine-dependent lipogenesis to reduce ER stress.

Dual activation of HIF2 and MYC seems to induce glutamine-dependent lipogenesis. Focal amplification was found of chromosome 8q24 in RCC specimens, which is the locus of the transcription factor MYC [4]. Overexpression of MYC in transgenic mouse models of RCC induced upregulation of glutaminases (GLS1-2) and transporters (SLC1A5) and elevated levels of glutamate and α -ketoglutarate [28]. Upregulation of glutamine metabolism was also accompanied by accumulation of lipids in RCC tumors [28]. In addition to MYC, a role has been identified for HIF2 in glutamine-dependent lipogenesis [29]. Expression of a constitutively active HIF2 molecule followed by metabolic flux analysis, revealed a shift of IDH/ACO towards reductive carboxylation of glutamine to citrate [29]. Experiments with labeled glutamine isotopes showed increased production of lipogenic acetyl-coA upon expression of this active HIF2 molecule [29]. Furthermore, HIF2 is known to enhance transcriptional activity of MYC directly through increased promoter binding [30]. Altogether, this information implicates a concerted effort of HIF2 and MYC in activation of glutamine-dependent lipogenesis.

The activation of mTOR may also contribute to the metabolic phenotype of RCC tumors. Isolated activation of mTORC1 through TSC1/2 knock out induced a gene

expression profile consistent with aerobic glycolysis [31]. Subsequent analysis of target genes combined with functional interference experiments revealed that HIF1 is responsible for the glycolytic response in this model [31]. Upregulation of HIF1 and HIF2 protein levels were thought to be induced by mTORC1-mediated inhibition of 4E-BP1 [31]. SREBP1/2 were other critical players that were found to act downstream of mTORC1. The latter transcription factors were found to drive the gene expression of G6PD and FASN [31] (Figs. 1 and 2).

Studies focusing on down- and upstream signaling partners of mTORC1 also claimed a role in regulation of metabolism. AKT is an example of an upstream signaling partner of mTORC1, which indirectly promotes its activity through inhibition of TSC2 [32]. Activity of AKT correlated with expression of glucose transporters (GLUT1), hexokinase (HK), and PFK1 in cancer cells (Fig. 2) [33–35]. Isolated overexpression of activated AKT stimulated aerobic glycolysis and rendered cells susceptible to glucose withdrawal [36]. AMPK on the other hand is a player that negatively affects mTORC1 signaling. It reduces mTORC1 activity through TSC2. Enhanced AMPK activity rescued cancer cells from AKT-dependent glucose addiction through activation of beta-oxidation of fatty acids [37]. These results suggest that the TSC2-mTORC1 axis is of importance for the impact of AKT on tumor metabolism. Decreased protein expression of AMPK and activating mutations in the PI3K-AKT-MTOR pathway are frequently observed in RCC tumors [4]. These results provide at least circumstantial evidence that mTORC1, although partly through HIF-mediated mechanisms, contributes to the metabolic phenotype of RCC tumors.

Part II. Targeting metabolic reprogramming in preclinical models

GLUT-1 and hexokinase inhibitors

Uptake of glucose is primarily mediated by the GLUT-1 transporter, which can be targeted by drugs. Selective

blocking of this transporter by the drug STF-31 was found to impede glucose uptake and selectively inhibit growth of RCC tumors [38]. Fasentin and WZB117 are other GLUT1-inhibitors with comparable effects on intracellular glucose levels. WZB117 induced activation of the ATP-sensing enzyme AMPK in lung cancer xenografts, indicating that it induces metabolic stress [39]. A direct comparison of these drugs has not been performed.

Hexokinase commits glucose to the glycolytic pathway and has been target of treatment for several decades. Particularly, the chemically modified glucose analog 2-deoxy-D-glucose (2DG) is a drug with a long-standing history in cancer research. The additional hydroxyl-group in 2DG prohibits metabolism after phosphorylation by hexokinase. The chemical modification thereby induces accumulation of 2-deoxy-glucose-6-phosphate, which inhibits hexokinase activity. No recent results have been published on application of the drug in preclinical RCC models. The drug 3-bromopyruvate (3-BrPa) is a second drug that interferes with hexokinase activity. Four isoforms of hexokinase have been identified to date. Hexokinase 2 was found to associate with anion channels at mitochondria, which appears important for mitochondrial homeostasis [40]. While 2DG acts as substrate for hexokinase, 3-BrPa is believed to interfere directly with its enzymatic activity and covalently bind hexokinase 2, which disrupts its association with mitochondria [40]. MCT1 facilitates import of 3-BrPA and its expression is therefore of crucial importance for sensitivity to the drug [41]. Treatment with 3-BrPa markedly reduced ATP production and induced cell death in primary RCC cell lines [42]. Lonidamine (LND) is the third drug that interferes with hexokinase activity. Application depleted intracellular ATP levels through inhibition of hexokinase 2 (HK2) and induced accumulation of lactate in cells [43]. A comparison between 3-BrPA and LND in glioblastoma cell lines revealed a different mechanism of cell death [44]. Accumulation of lactate and the different cell death mechanism suggest additional effects of LND on cellular metabolism in addition to HK2 inhibition. LND has not been tested in preclinical RCC models.

Inhibitors of the pentose phosphate pathway

G6PD and TKT are critical enzymes in the pentose phosphate pathway, whose activity can be blocked by drugs. Activity of hexokinase delivers glucose-6-phosphate which can be directed into the PPP (Fig. 3). The pathway consists of two distinct phases. G6PD is the rate-limiting enzyme in the oxidative phase, which generates NADPH and ribul-5-p. TKT acts as a critical enzyme in the second non-oxidative phase, which serves to recycle ribul-5-p back to the glycolysis through generation of Fru-6-p (Fig. 3). Silencing of TKT in hepatocellular carcinoma





Fig. 2 Connections between the PI3K- and metabolic pathways are shown. Given their central role in the pathogenesis of RCC, p110 α , Akt, and mTORC1 are labeled orange



cells induced accumulation of ribul-5-p and rib-5-p [45]. Importantly, TKT and TALDO were found to function as bidirectional enzymes, having the ability to promote the reverse reaction. Depending on the metabolite balance in cancer cells, inhibition of TKT therefore may not necessarily reduce the production of Fru-6-p.

6-Aminonicotinamide (6-AN) and dehydroepiandrosteron (DHEA) are G6PD inhibitors that have been tested as experimental treatment. The drug 6-AN elevated oxidative stress in RCC cell lines through a decrease in NADPH [46], which is a known product of the PPP. Novel small molecule inhibitors with favorable pharmacokinetic properties are in development [47]. HDM2 antagonists are another class of drugs that may reduce G6PD activity. They induce accumulation of p53, which directly interacts with G6PD and blocks its function [48]. HDM2 antagonists such as MI319 have been tested in combination with sunitinib in RCC xenograft models and showed potent reduction of tumor growth [49]. Beneficial effects of HDM2 inhibitors could, however, also be mediated by other p53-dependent effects.

TKT is the second critical enzyme in the pentose phosphate pathway. Oxythiamine and hydroxyphenylpyruvate are examples of TKT inhibitors. Oxythiamine was found to be an effective treatment in hepatocellular carcinoma xenografts. Here, it reduced tumor growth through elevation of oxidative stress [45]. Treatment of Ehrlich's ascitic tumor cells with

oxythiamine significantly reduced the synthesis of ribose, which is a main product of the PPP and an important source for nucleic acid catabolism [50]. A variant of this thiamine analog has been generated with improved TKT specificity, but requires further investigation in preclinical models [51].

Inhibitors of glycolytic enzymes

PFK1 catalyzes the production of fructose-1,6-bisphosphate (Fru-1,6-P₂) from fru-6-p. The bidirectional enzyme PFK2-FBase regulates the production of fructose-2,6-bisphosphate (Fru-2,6-P₂) from fru-6-p. Fru-2,6-P₂ stimulates glycolysis through allosteric activation of PFK1 (Fig. 3). Four different isoforms of PFK2-FBase are known to be expressed in human tissues. The PFK-FB3 isoform was found to be preferentially expressed in cancer cells. The drug PFK15, as well as its predecessor 3PO, interferes with the enzymatic function of the kinase. As a consequence of treatment, reduced intracellular Fru-2,6-P₂, lactate and ATP levels were detected in leukemic-, lung-, and breast cancer cells, which confirms on-target effects [52]. Treatment also induced potent antitumor effects in multiple xenograft models of cancer [53].

Fructose-bisphosphate-aldolase, GAPDH, PGK, phosphoglycerate mutase (PGAM1), and ENO1 are other enzymes involved in glycolytic reactions (Fig. 3). Small molecule inhibitors of GAPDH (FK866), PGAM1 (PGMI-004A), and ENO (ENOblock) have been

discovered [54–56]. Pharmacological blockade of PGAM1 reduced glycolysis and resulted in accumulation of 3-phosphoglycerate (3-PG). Unexpectedly, PGAM1 inhibitors activated a feedback loop that reduced 6-phosphogluconate dehydrogenase (6-PGDH) activity and flux through the PPP [56]. A shift in the melting temperature of 6-PGDH was found in the thermal melt assay upon incubation with increasing concentrations of 3-PG. Further crystal structure analysis confirmed direct binding of 3-PG to 6-PGDH at sites important for enzymatic activity. Blockade of the PPP at the level of 6-PGDH through a toxic buildup of 3-PG therefore seems a mechanism for this activity [56].

PK catalyzes the final reaction in glycolysis and therapeutic strategies have been developed that target PK. In normal cells, PK generates ATP and pyruvate through dephosphorylation of phosphoenolpyruvic acid (PEP). The M2 isoform (PKM2) was shown to be preferentially expressed in cancer cells and promote aerobic glycolysis [57]. Interestingly, it was not its enzymatic activity but rather its ability to bind phospho-tyrosine proteins that was shown to promote aerobic glycolysis (Fig. 2) [58, 59]. Expression of PKM2 protein was found to be increased in human RCC specimens [15]. A systematic search for small molecules that selectively target PKM2 yielded numerous compounds that mimicked gene silencing in lung cancer cells [60]. Activation of enzymatic activity was also shown to serve as potential therapeutic strategy. PKM2 activity is known to be stimulated by upstream Fru-1,6-P2 through binding to a unique domain, which induces a conformational change. Compounds have been developed that mimic Fru-1,6-P2 activity in lung cancer cells and lock PKM2 in its active state [61]. Activation of PKM2 was shown to create a unique dependence of cancer cells on extracellular serine, most likely through reduced availability of 3-PG [61]. Tests of PK-M2 targeting strategies in xenografts and preclinical RCC models are lacking, and therefore, their role in this disease still has to be determined.

Inhibitors of pyruvate and lactate metabolism

PDH converts pyruvate into acetyl-coA, while LDH transforms it into lactate. PDK inactivates PDH through its phosphorylation. Therapeutic strategies that interfere with pyruvate metabolism have focused on PDK in order to promote use of the TCA cycle. Downregulation of PDK both increased respiration and oxidative stress through activation of the TCA cycle [62]. Dichloroacetic acid (DCA) is an example of a PDK inhibitor that acts as pyruvate mimetic. DCA was found to reverse mitochondrial suppression and reduce tumor size of preclinical RCC xenografts [63]. AZD7545 and VER-246608 are other drugs that inactivate PDK through binding at different structural sites [64]. VER-246608 is an ATP-

competitive PDK inhibitor, which enhanced PDH activity and cellular respiration and attenuated glycolytic activity in cancer cell lines [65].

LDH catalyzes the final step of aerobic glycolysis and represents another attractive target for treatment (Fig. 3). Similar to PDK inhibitors, downregulation of LDH-A was found to promote respiration in FH-deficient RCC cells [66]. At least two small molecule inhibitors have been tested in preclinical models. AT-101 or gossypol is an unspecific inhibitor of multiple dehydrogenase enzymes, including LDH-A. Its derivative FX11 is an example of a LDH-inhibiting compound, that was successfully tested in RCC models [67]. Treatment increased oxygen consumption and oxidative stress, indicating that pyruvate is shunted into the TCA cycle. Oxamate represents a second example of a promising LDH-inhibitor. Treatment induced similar metabolic results as found with FX11 with additional activation of autophagy in NSCLC cells [68]. *N*-hydroxyindole-2-carboxylates (NHI) are currently under investigation as next-generation LDH inhibitor. Epigallocatechin gallate (EGCG) may also have activity as LDH inhibitor but was found to interfere with other metabolic enzymes. Its utility as LDH inhibitor remains to be shown.

Under physiological circumstances, lactate, as well as glycerol, can be employed for gluconeogenesis. The mitochondrial enzyme glycerophosphate dehydrogenase (GPDH) converts glycerol-3-phosphate (glyc-3-p) into dihydroxyacetone phosphate (DHAP) (Fig. 4). This reaction yields significant amounts of NAD⁺, which is required for the production of glucose from lactate. The antidiabetic drug metformin was found to block gluconeogenesis through specific targeting of the mitochondrial isoform of GPDH [69]. Secondary to these effects, AMPK activation was found in cancer cells treated with metformin, restraining mTORC1 signaling and limiting growth of renal cell cancer xenografts [70]. The importance of a functional AMPK-TSC1-mTORC1 pathway for metformin has been illustrated by the lack of response in a TSC1(+/-) transgenic model [71]. Frequent downregulation of AMPK has been observed in RCC and therefore makes the potential of the drug in RCC questionable.

Inhibition of lactate transport has been investigated as therapeutic strategy. The monocarboxylate transporters 1 and 4 (MCT1/4) facilitate lactate export from cancer cells and prevent a toxic buildup of the metabolite (Fig. 3). Downregulation of the MCT4 (SLC16A3) transporter was identified as therapeutic strategy through whole genome siRNA screens in RCC cell lines [72]. Lactate export is accompanied by H⁺ transport across the plasma membrane. Through interference with intracellular pH, rapid cytotoxic effects are induced. AZD3965, *a*-cyano-4-hydroxy-cinnamate (CHC),




Fig. 4 A schematic overview of drugs that may interfere with glutamine-dependent lipogenesis

and AR-C155858 are examples of drugs that interfere with lactate export through blockade of MCT1. AZD3965 treatment effectively induced lactate accumulation in small cell lung cancer xenografts [73]. AR-C155858 and CHC curtailed lactate secretion along with lower pH levels and cytotoxic effects in multiple myeloma cells [74]. Effectivity of MCT1 inhibitors appears to rely on low MCT4 expression levels [75], which suggest some functional redundancy. Both transporters seem to be expressed in RCC [13, 72]. Interestingly, silencing of MCT4 expression alone did affect the viability of RCC cells [72]. Future research will therefore have to focus on development of MCT4 or potential dual MCT1/4 inhibitors for patients with RCC.

Arginine- and other amino acid-depleting treatment strategies

Metabolomics studies revealed decreased levels of almost all amino acids (except cysteine, glutamate, and glutamine) in RCC tumors as compared to normal kidney tissues [17]. In contrast, upregulation of genes involved in nucleotide and particularly pyrimidine synthesis was found in a meta-analysis of TCGA data [5]. Glutamine acts as source for nucleotide biosynthesis through conversion into TCA cycle intermediates [76]. ASS1 is an example of a gene involved in both amino acid and nucleotide metabolism. Downregulation of ASS1 has been detected in an independent analysis of RCC specimens [8]. ASS1 and downstream argininosuccinate lyase catalyze the conversion of aspartate into arginine. Lack of ASS1 results in accumulation of aspartate in the cytosol, which is subsequently directed into the pyrimidine and nucleotide synthesis

pathway [77]. Downregulation of ASS1 therefore promotes generation of nucleotide precursors and also makes RCC cells dependent on extracellular arginine.

Depletion of extracellular arginine, through administration of pegylated arginase 1 (Peg-Arg-1) or arginine deiminase (ADI), has been explored as an anticancer treatment. It has been tested in RCC xenograft models as therapeutic strategy [8]. Dose-dependent inhibition of tumor growth was observed. Reconstitution of ASS1 induced resistance to ADI in vitro. Similar treatment effects were seen in hepatocellular carcinoma (HCC) and melanoma xenografts, with a sustained decrease in intratumoral arginine levels [78]. Unfortunately, many immune cells rely on extracellular arginine [79]. Arginine depletion therapy therefore has immunosuppressive effects, which possibly limits its efficacy in mice.

Tumor cells meet their essential amino acid demands by upregulation of specific transporters. The L-type amino acid transporter 1 (LAT1) is an example of an up-regulated transporter in ccRCC [80]. It transports large neutral branched amino acids, such as the leucine and tryptophan. LAT1 recognizes amine and carboxylic acid side groups in substrates, which determines its selectivity. Drugs (JPH203, 3,5-diiodo-L-tyrosine, acivicin) have been developed that exploit this feature and competitively inhibit LAT1 activity. Treatment with JPH203 induced dramatic inhibition of leucine uptake and proliferation of colorectal cancer cells [81].

In line with the elevated expression of LAT1, increased tryptophan metabolism has been detected in RCC specimens [16]. Particularly, upregulation of the metabolic enzyme indoleamine 2,3-dioxygenase (IDO1) has been observed as a frequent feature [82]. This enzyme stimulates conversion of tryptophan into the immunosuppressive metabolite kynurenine [83], which was also found to be elevated in RCC [16]. The IDO-inhibitors L-1-MT, 1-D-MT, INCB024360, and indoximod have been developed and give various degrees of IDO-blockade. A decrease in kynurenine production was found in vitro [16, 84]. Effectivity of these inhibitors has not been tested in RCC xenograft models.

Inhibitors of glutamine metabolism

Glutamine analogs as well as inhibitors of physiological glutamine import have been used as therapeutic agents in preclinical studies. In addition to its function as an energy and lipid source, glutamine participates in many enzymatic reactions. The glutamine analogs 6-diazo-5-oxo-L-norleucine (L-DON, NSC 7365), acivicin (NSC 163501), and azaserine (NSC 742) block the function of glutamine utilizing enzymes (Fig. 4). Pharmacological in vitro studies using leukemia cells identified inhibition of amidotransferases and nucleotide biosynthesis as principal mechanism of action [85]. Import of glutamine into

cancer cells is exerted by SLC1A5 (ASCT2). Gamma-L-glutamyl-*p*-nitroanilide (GPNA) and benzylserine (H-Ser(Bzl)-OH) are targeted inhibitors of this transporter that reduce growth of lung cancer xenografts. GPNA treatment of lung and prostate cancer cells diminished glutamine consumption and generation of fatty acids and induced autophagy, suggesting that it causes metabolic stress [86, 87]. None of these inhibitors has been tested in preclinical RCC models.

Glutaminase (GLS) is the enzyme involved in the conversion of glutamine into glutamate (Fig. 4). It can be targeted with the chemical inhibitors bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES), bromo-benzophenanthridinone 968 and CB-839. The inhibitor BPTES has been successfully tested in preclinical RCC models. It suppressed growth of RCC xenografts in two independent studies [28, 29]. Application of BPTES in glioblastoma cell lines reduced glutaminase activity with reduced glutamate and α -ketoglutarate production [88]. Similar results have been obtained with CB-839 in breast cancer cells [89].

Glutamate dehydrogenase (GDH) converts glutamate into α -ketoglutarate (Fig. 4). Hexachlorophene, GW5074 and bithionol are GDH-inhibitors. Their structure was based on the green tea polyphenol epigallocatechin gallate (EGCG). This drug has frequently been used in preclinical experiments as GDH-inhibitor [90, 91], although it may have a variety of other effects in cancer cells. Amino oxycetate (AOA) is a well-characterized inhibitor of transaminases [92]. AOA was shown to affect glutamate metabolism via a pathway involving an aminotransferase, presumably aspartate aminotransferase [93]. Both AOA and EGCG effects were shown to be rescued by supplementation of molecules such as α -ketoglutarate or oxaloacetate, supporting specific effects on glutamine metabolism [91, 94].

Oxalomalate and 2-methylisocitrate are NADPH-competitive IDH inhibitors. Reductive carboxylation of α -ketoglutarate by IDH was shown to be the dominant pathway for generation of citrate and lipids in RCC cells [27, 95]. Both oxalomalate and 2-methylisocitrate reduced integration of isotope-labeled glutamine into citrate and lipids in adipocytes [96]. Discovery of IDH1 mutations in certain diseases urged development of mutant specific inhibitors such as AGI-5198 IDH C-35, AG120, and AG221. Limited affinity for wild-type IDH1/2, such as observed in RCC, was found, leaving little room for application in this disease [97]. In addition to citrate, 2-hydroxyglutarate (2-HG) is produced during reductive carboxylation of α -ketoglutarate [95]. Accumulation of 2-HG was found in RCC cells, which was mainly attributed to decreased expression of the degrading enzyme 2-HG dehydrogenase (L2HGDH) [98]. No therapeutic strategies have been developed to target this last enzymatic process.

Inhibitors of lipogenesis

Citrate can be transported out of the mitochondria and cleaved to acetyl-coA by ATP citrate lyase (ACLY). Activity of ACLY can be blocked by the chemical inhibitors SB-204990 and SB-201076. The depletion of ACLY inhibits proliferation of lung-, liver-, and prostate cancer cells under lipid-deprived growth conditions, supporting a crucial role in lipogenesis [99]. Significant reductions in acetyl-coA levels were found in cancer cells after treatment with the chemical ACLY inhibitor SB-204990 [100]. Single agent activity was shown in lung and prostate cancer xenograft models with predominantly cytostatic effects [100]. No results have been published with these agents in RCC models.

ACC carboxylates acetyl-coA to form malonyl-coA. Its expression was independently associated with worse clinical outcome of patients with RCC. Three chemical inhibitors of ACC have been tested as anticancer treatment. Downregulation of ACC through RNA interference or with the chemical inhibitor sorafen A attenuated fatty acid synthesis and proliferation of prostate cancer cells [101]. The cytotoxic effects were abolished by supplementation of culture media with fatty acids, which supports interference with lipid metabolism as the principal mechanism of action. CP-640186 and TOFA are the other two chemical inhibitors that have been tested in preclinical liver and breast cancer models [9, 102]. Treatment of breast cancer cells with TOFA reduced malonyl-coA levels [103], confirming on-target effects of this drug.

FASN converts malonyl-coA to long-chain fatty acids. Inhibition of FASN by cerulin or its derivative C75 induced a rapid increase in malonyl-coA with a marked reduction in lipogenesis in multiple cancer models, including RCC cells [103, 104]. In addition to effects on lipogenesis, accumulation of malonyl-coA may have cytotoxic effects in itself. Orlistat, GSK 837149A, G28UCM, and triclosan are other FASN inhibitors that have shown to limit proliferation of prostate and ovarian cancer cells [105–107]. Consistent with inhibition of de novo fatty acid synthesis, G28UCM and C75 treatment caused conversion of membrane lipids into storage lipids in ovarian cancer cells [107]. A reduction in overall lipid content was found after triclosan and C75 treatment in prostate cancer cells [105].

Inhibitors of the PI3K-AKT-mTOR pathway

Due to the abundance of molecular alterations in the PI3K-AKT-mTOR pathway in RCC, several therapeutic strategies have been explored. Many of the inhibitors described below exhibit cross-activity against other components of the pathway (for example, dual PI3K/mTOR inhibitors). More information about the pharmacological aspects of these drugs can be found elsewhere. Activating mutations in p110 and p85 subunits of PI3K as well

as inactivating mutations in the PTEN phosphatase presumably render tumors susceptible to targeted inhibitors. Indeed, promising results have been achieved with PI3K-inhibitors such as NVP-BEZ235, GDC-0980, and LY294002 in renal cell cancer models [108–112]. Perifosine (KRX-0401) is an example of an AKT inhibitor that has been described to reduce proliferation of RCC cells [113]. Clinical activity of rapalogs (temsirolimus, everolimus) in patients with RCC elicited development of next-generation mTOR inhibitors. Particularly enhanced activity against mTORC2 seems to improve efficacy and these agents are therefore awaiting clinical tests. WYE-125132, WYE-354, P7170, and AZD8055 are examples of novel mTOR inhibitors that induced tumor shrinkage in preclinical RCC models [114–117].

Part III. Clinical trials on metabolic inhibitors

Clinical experience with metabolic inhibitors

Many of the drugs that were tested in early stages of drug development in oncology were targeting metabolic components of tumors. New insights from molecular profiling of numerous diseases and preclinical experiments may urge a revival of drugs from this era. Although these drugs have been tested in the clinic, it remains uncertain whether dosing, treatment schedule, tumor type, and response evaluation in these trials were adequate. In the ideal situation, one prefers to evaluate on-target effects in patient-derived tumor tissue. This last action may differentiate between suboptimal dosing regimens, pharmacologically inferior drugs, and unviable drug targets. From common genetic polymorphisms that are known to confer a clinical phenotype, such as the single nucleotide polymorphisms (SNP) in the G6PD gene that may cause severe hemolytic anemia, one may anticipate toxicity of certain inhibitors due to on-target effects. These on-target effects on non-tumor tissue are unwanted during treatment but can be very informative for evaluation of pharmacodynamic effects. Occurrence of certain side effects (e.g., hemolytic anemia in G6PD blockade) in early clinical trials may tell whether the investigators reached proper blockade of the target during the treatment. Both efficacy and toxicity may therefore provide valuable information for design of clinical trials with these agents or their improved counterparts.

The glucose analog 2-deoxy-D-glucose (2DG) is an example of a drug that has received renewed attention lately (see Table 1 for an overview). A traditional dose escalation study was performed among patients with advanced cancer as single agent as well as in combination with docetaxel [118, 119]. On a daily dosing schedule of 45–60 mg/kg, plasma concentrations of 0.7 mM were reached which approximates concentrations used for preclinical RCC experiments [118, 120]. Dose-limiting toxicities (DLTs) were fatigue, sweating, dizziness,

Table 1 Overview of drugs, currently in clinical development

Drug	Target	Clinical stage	RCC
2DG	Glucose	Phase 2	n.a.
Lonidamine	HK	Phase 2	Negative
Dichloroacetate (DCA)	PDK	Phase 3	n.a.
Polyphenon E	LDH-A	Phase 1	n.a.
FK866	GAPDH	Phase 1	n.a.
AT-101	LDH-A	Phase 2	n.a.
PEG-ADI	Arginase 1	Phase 3	n.a.
Indoximod	LAT1	Phase 2	n.a.
Acivicin	Glutamine	Phase 2	Negative
6-Diazo-5-oxo-L-norleucine (DON)	Glutamine	Phase 2	n.a.
Orlistat	FASN	Phase 1	n.a.
Metformin	GPDH	Phase 3	n.a.
NVP-BEZ235	PI3K/mTOR	Phase 2	n.a.
GDC-0980 (apitolisib)	PI3K/mTOR	Phase 2	n.a.
SF1126	PI3K	Phase 1	n.a.
BYL719	P110a	Phase 2	n.a.
MLN1117	P110a	Phase 2	n.a.
AZD8186	p110 β	Phase 1	n.a.
GSK2636771	p110 β	Phase 2	n.a.
SAR260301	p110 β	Phase 1	n.a.
Perifosine	Akt	Phase 2	Negative
MK-2206	Akt	Phase 2	n.a.
GSK690693	Akt	Phase 1	n.a.
GDC-0068	Akt	Phase 2	n.a.
BEZ235	PI3K/mTOR	Phase 2	n.a.
XL765	PI3K/mTOR	Phase 1	n.a.
GDC0890	PI3K/mTOR	Phase 2	n.a.
GSK1059615	PI3K/mTOR	Phase 1	n.a.
AZD8055	mTORC1/2	Phase 1	n.a.
AZD2014	mTORC1/2	Phase 2	Negative

nausea, and prolonged QTc time. These results suggest that 2DG may induce hypoglycemic symptoms due to competition with systemic glucose. PET imaging in a limited number of patients showed reduced uptake of fluoro-deoxy glucose (FDG), indicative of potential competition between FDG and 2DG in tumors. No phase 2 study has been performed with this drug in RCC.

Lonidamine is another revived chemotherapeutic agent, which is supposed to target hexokinase in tumors. Phase 1 clinical trials have been conducted in the 1980s as single agent as well as combined with whole body hyperthermia [121–123]. Safety was confirmed of chronic use of oral doses up to 360 mg/m², yielding systemic concentrations of 5.13 μ g/mL. Side effects consisted mostly in musculoskeletal discomfort, anorexia, testicular pain in males, and a reversible ototoxicity. No metabolism or target

inhibition analyses were performed in patients. Two phase 2 studies have been performed among patients with RCC, showing limited clinical activity of the drug [124, 125]. One year survival rate was 37.5 % in patients treated with lonidamine which relates unfavorable to current treatment strategies [124]. Limited information is available on RCC subtype and patient characteristics (e.g., Heng prognostic score) in these trials. The results therefore have to be interpreted with caution.

The small molecule PDK-inhibitor dichloroacetate (DCA) is registered for patients with congenitally dysfunctional PDH. Safety and tolerability has also been tested in patients with advanced solid tumors [126]. The maximum tolerated dose was 6.25 mg/kg with fatigue, nausea, and grade 3 neuropathy as dose limiting toxicity at higher dose levels. Pharmacokinetic analysis revealed high variability in systemic drug concentrations, possibly related to common genetic polymorphisms in the GSTZ1/MAAI metabolic enzyme [126, 127]. Preliminary analysis of glioblastoma tissue from three patients treated with DCA showed stimulation of PDH activity and accumulation of α -ketoglutarate and hydrogen peroxide [128]. Further research is warranted to determine efficacy of the drug as potential therapeutic agent.

Based on the cancer preventive as well as therapeutic activity of the multitargeted agent epigallocatechin gallate (EGCG), phase 1 clinical trials have been conducted. Most clinical trials used polyphenon E as a defined decaffeinated green tea polyphenol mixture. Doses up to 2000 mg twice daily were well tolerated with predominantly mild to moderate gastrointestinal side effects such as diarrhea and nausea [129, 130]. No dose-limiting toxicities or pharmacodynamic results have been reported. The oral bioavailability was shown to be poor with large variability and a median plasma through concentrations of 40.4 ng/mL [130]. Although uptake was shown to be improved by fasting prior to intake, concentrations relate unfavorable to preclinically effective levels (5–50 times higher) [131]. Alternative pharmacological prescriptions are warranted for intravenous testing and maximum tolerated dose (MTD) determination. Current polyphenon formulations are most likely insufficient for proper clinical trials in RCC.

Metformin is a commonly used antidiabetic drug that was found to have anticancer activity. Its favorable side-effect profile and abundant clinical experience has urged start of clinical trials. Beneficial effects of metformin doses up to 2000 mg per day have been observed on the regulation of diabetes mellitus. Retrospective cohort studies have confirmed potential anticancer activity of these doses in numerous patient cohorts. In a large renal cell cancer cohort, prolonged overall survival was seen in patients with localized disease but not in patients with metastatic disease [132]. Prospective phase 2 trials have

been conducted, assuming maximum anticancer effects at commonly used antidiabetic doses. No prospective clinical trials have been done in RCC. Disease stabilization has been observed as best response among patients with prostate cancer, while no clinical activity was found in patients with pancreatic cancer [133, 134]. The correlation between AMPK expression and treatment response has not been subject of these analyses.

FK866 and AT-101 are two other drugs that have reached the early stages of clinical testing. AT-101 represents an unspecific inhibitor of dehydrogenases, including LDH-A. A phase I/II clinical trial among patients with prostate cancer showed an MTD of 20 mg/day [135]. Diarrhea, fatigue, nausea, and anorexia were the most frequently observed adverse events. The GAPDH and NAD-inhibitor FK866 was administered as a continuous intravenous infusion over 96 h. Thrombocytopenia was the dose limiting toxicity, yielding an MTD of 0.126 mg/m²/hour [136]. In addition, lymphopenia, anemia, and liver test abnormalities were observed. No metabolic analysis was performed during treatment with these inhibitors.

Pegylated arginine deiminase (PEG-ADI) and the IDO-inhibitor indoximod are drugs that underwent phase 1/2 clinical testing. Increasing doses of the arginine depleting enzyme PEG-ADI were given to 31 patients with melanoma with ASS1 negative tumors [137]. Pharmacodynamic analysis revealed neutralization of systemic arginine in 30/31 patients at day 8 after the start of treatment. No RECIST based responses were measured [137] with eight patients having stable disease as best response. No dose-limiting toxicities were seen during treatment. Indoximod has also been subject of a phase 1 clinical trial in 48 patients with advanced solid tumors [138]. The maximum tolerated dose was 2000 mg twice daily. Hypophysitis, tumor antigen autoantibodies, and elevated CRP levels were observed at several dose levels and suggest a reduction of immunosuppressive effects in tumors. Phase 2 clinical trials are underway.

Acivicin and 6-diazo-5-oxo-L-norleucine (DON) are glutamine antagonists that have been tested in patients with cancer. Acivicin and DON can both be isolated from *Streptomyces sviveus* bacterial cultures and are structurally related to glutamine. Dose escalation studies among patients with advanced cancer revealed MTDs of 600 mg/m² for DON [139]. Multiple dosing regimens have been used for treatment with acivicin. Doses ranging from 15 mg/m²/day on five consecutive days to 160 mg/m²/day as single 24-h infusions were recommended by these studies [140, 141]. Acute dose-dependent nausea, vomiting, and diarrhea were DLTs after treatment with DON. Acivicin induced myelosuppression and neuropsychiatric symptoms (paresthesia, weakness, hallucinations, psychosis, confusion) as dose-limiting

toxicities. These last symptoms were attributed to the potential neurotransmitter like properties of acivicin. Concomitant intravenous administration of amino acid mixtures was shown to reduce CNS toxicity and therefore allowed further dose escalation [142]. Pharmacodynamic analysis of amidotransferase activity in ascites derived tumor cells showed suppression by acivicin [140]. A randomized phase 2 trial has been performed with acivicin among patients with advanced RCC [143]. One partial response was observed after treatment with 20 mg/m² for 72 h among 27 patients.

The FASN inhibitor orlistat is a drug that is approved for weight management in over 120 countries. A randomized double blind study among 539 obese individuals showed safety and good tolerability of the drug at a dose of 120 mg once daily [144]. However, negligible systemic absorption renders the oral drug unsuitable for treatment of patients with cancer [145]. Further research is needed to determine potential use of alternative pharmacological formulations of this drug.

Clinical experience with PI3K-AKT-mTOR inhibitors

As downstream mediator of receptor tyrosine kinase (RTK) signaling as well as mutated hotspot itself, PI3K represents an attractive therapeutic target. A variety of inhibitors, including the previously described drugs NVP-BEZ235, GDC-0980, and SF1126, have entered clinical trials. PI3K targeting drugs can be divided in pan-PI3K- and isoform-specific PI3K inhibitors. Multiple pan-PI3K inhibitors underwent phase 1 and 2 clinical testing and showed limited toxicity and at best modest clinical activity [146]. Dose-limiting effects included hyperglycemia, maculopapular skin rash, and gastrointestinal intolerance (nausea, anorexia, diarrhea) [147–150]. AKT phosphorylation in blood, skin, or tumor tissue has been used as pharmacodynamic biomarker and showed a decrease, ranging from 40 to 90 %. FDG-PET imaging also showed marked metabolic responses in a small subset of patients [147]. Whether these effects are sufficient to induce durable treatment responses in patients with RCC is questionable. It has been conjectured that the essential role of PI3K in healthy tissues may limit dosing and restrict impact on tumors. Recent success with the δ -isoform-specific PI3K-inhibitor idelalisib in hematological malignancies [151] urged investigation of such specific inhibitors in solid tumors as strategy to circumvent these potential limitations of pan-PI3K inhibition. RCC tumors are known to harbor frequent PTEN and PIK3CA mutations. Previous research indicated that PTEN loss should be targeted by p110 β -inhibitors [152], while PIK3CA mutations ask for p110 α selective inhibitors [153]. The first clinical results of p110 α selective (BYL719, MLN1117) and p110 β -selective (AZD8186, GSK2636771, SAR260301) inhibitors are now emerging.

Phase 2 clinical trials in patients with RCC will be required to further elucidate the role of these inhibitors in this disease.

AKT acts as critical downstream mediator of PI3K and has been postulated as “the Warburg kinase.” Perifosine and MK-2206 are examples of AKT inhibitors that were subject of phase 1 clinical trials [154, 155]. GSK690693 and GDC-0068 are ATP-competitive AKT inhibitors targeting all three isoforms that are currently under investigation. Dose-limiting toxicities were skin rash, nausea, diarrhea, pruritus, and hyperglycemia. AKT phosphorylation declined in tumor biopsies after treatment with MK-2206 [154]. Two phase 2 trials were conducted with perifosine among patients with RCC, showing limited clinical activity of the drug. No metabolic analysis has been performed in studies that employed AKT inhibitors. Preclinical studies suggested AKT-independent signaling pathways in PIK3CA mutated cell lines, possibly explaining limited clinical activity of perifosine [156].

Preclinical experiments suggest improved antitumor activity of dual targeting of PI3K/mTOR or mTORC1/mTORC2. Mutation of PIK3CA predisposes to a favorable response to rapalogs [157]. An elevated systemic LDH level before start of treatment was found to be associated to overall survival of patients with RCC treated with temsirolimus [158]. In both publications, the authors speculated that the biomarkers are indicative of pathway activation, which may explain their association with response to mTOR inhibitors. The drugs BEZ235, XL765, GDC-0890, and GSK1059615 are examples of dual PI3K/mTOR inhibitors. Phase 1 results from clinical tests with BEZ235 and XL765 have been published and showed similar toxicity profiles as with pan-PI3K inhibitors [159, 160]. AZD8055 and AZD2014 are examples of dual mTORC1/2 inhibitors that went through phase 1 testing [161, 162]. AZD2014 was shown to inhibit p-S6 in tumor biopsies. A randomized phase 2 trial has been conducted with AZD2014, comparing its efficacy with everolimus [163]. The clinical trial was stopped early due to inferior activity of AZD2014 in this patient cohort, despite adequate systemic drug concentrations. No results of pharmacodynamic analysis of tumor tissue were described.

The impact of VEGF and mTOR inhibitors on tumor metabolism

Molecular profiling studies identified metabolic alterations as poor prognostic parameters. It has been suggested that upregulation of aerobic glycolysis and lipogenesis are part of the natural disease course and may aid in tumor progression. Most of these studies were performed in the era of targeted therapy, with VEGF-targeted drugs and mTOR inhibitors as established treatment modalities. Treatment poses selective

pressure, allowing expansion of certain clones with advantageous molecular features. We here briefly review drug resistance against VEGF- and mTOR-targeted inhibitors and its role in directing tumor metabolism.

VEGF-targeted drugs are known to interfere with angiogenesis, significantly compromising oxygen and nutrient supply. Aerobic glycolysis seems an efficient way to cope with certain aspects of these types of metabolic stress, since it requires little oxygen. A comprehensive analysis of the impact of VEGF-targeted agents on tumor metabolism has been performed in lung and breast cancer xenografts. Upregulation of glycolysis and lipogenesis was found during treatment with the VEGF inhibitors sunitinib or sorafenib in this study [164]. Similarly, the VEGF-neutralizing antibody bevacizumab was shown to promote lactate production and activation of the PI3K-pathway in glioblastoma xenografts [165, 166]. Analysis of RCC tumor tissue after treatment with erlotinib and bevacizumab revealed an association between poor treatment response and low AMPK expression or activation of the PI3K-pathway. Sequential FDG-PET imaging during sunitinib treatment in patients with RCC showed high glucose uptake associated with poor treatment response [167]. These observations indicate that VEGF-targeted drugs may aid in selection of tumor cells with altered metabolism and/or activation of PI3K. Treatment with orlistat, DCA, and PI3K inhibitors restored the sensitivity to VEGF-targeted drugs in preclinical models, demonstrating potential of combination treatment strategies [164, 166, 168].

The rapalogs everolimus and temsirolimus interfere with mTOR signaling in tumor cells. Multiple resistance mechanisms have been identified in the last decade. These mechanisms include activation of MAPK-pathway through a PI3K-mediated feedback loop and increased survivin expression [169, 170]. TSC1/2 mutations were shown to predispose to a favorable treatment response [171]. Furthermore, mTOR acts as an energy sensor in cells and its inhibition leads to the activation of salvage pathways for the generation of energy, such as autophagy or utilization of extracellular amino acids [172, 173]. Functional interference with these salvage pathways can result in synthetic lethal effects in cancer cells. For example, severe cytotoxic effects of combined autophagy- and mTOR inhibition have been detected in mantle cell lymphoma cells [174]. Similarly, targeting compensatory upregulation of glutamine metabolism in glioblastoma xenografts induced severe cytotoxic effects [175]. The implications of “the metabolic shift” in RCC for the sensitivity to mTOR inhibitors, or the impact of mTOR inhibitors on metabolism are currently unknown and warrant further investigation.

Conclusions

Molecular profiling studies have uncovered a pronounced metabolic shift in tumors of patients with ccRCC. Aerobic glycolysis, upregulation of lipogenesis and activation of the PI3K pathway are hallmarks of the disease. HIF1/2, MYC, and mTOR are deemed essential players in this feature. Preclinical research has revealed several promising therapeutic targets in these pathways, among them G6PD, PFK-FB3, and LDH-A. Several therapeutic agents showed promising pharmacodynamic effects and have been tested with success in preclinical models of RCC and are therefore awaiting clinical evaluation. Particularly, dual inhibitors of PGAM1 and 6-PGDH (e.g., PGMI-004A) and inhibitors of the relatively cancer-specific target PFK-FB3 such as PFK15 warrant further investigation. Disappointing results have been obtained in clinical trials with a number of drugs (e.g., orlistat, polyphenon E) due to a suboptimal pharmacological formulation. In other clinical studies a thorough pharmacodynamic analysis during treatment was lacking, limiting the possibility to draw conclusions on the viability of the drug targets. Novel PI3K-AKT-mTOR inhibitors have arrived in the clinic. Thus far, the results have however been disappointing, possibly due to a lack of tumor- or drug target-specificity. Future trials will rely on careful design, proper patient selection, and thorough analysis of the pharmacodynamic effects of drugs in order to shift paradigms and move towards new treatment regimens. To this end, combined molecular characterization before start and after treatment may be of critical importance for adequate treatment selection. Given the fact that metabolic remodeling in RCC carries a poor prognosis and aids in disease progression, therapeutic agents that interfere with this process may shape the future of patients with advanced RCC.

Abbreviations

2DG, 2-deoxy-D-glucose; 3-BrPa, 3-bromopyruvate; 6-AN, 6-aminonicotinamide; 6-PG, 6-phosphogluconate; 6-PGDH, 6-phosphogluconate dehydrogenase; ACAT1, acetyl-coA acetyltransferase; ACC, acetyl-CoA carboxylase; ACLY, ATP citrate lyase; ACO2, aconitase 2; ADI, arginine deiminase; AMPK, AMP-activated kinase; AOA, amino oxacetate; BPTES, bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide; ccRCC, clear cell renal cell cancer; CHC, a-cyano-4-hydroxy-cinnamate; DCA, dichloroacetic acid; DHEA, dehydroepiandrosteron; EGCG, epigallocatechin gallate; ENO1, alpha-enolase; ER, endoplasmic reticulum; FASN, fatty acid synthesis; FDG, fluoro-deoxy glucose; Fru-2,6-P2, fructose-2,6-bisphosphate; G6PD, glucose-6-phosphate dehydrogenase; GAPDH, glyceraldehyde-phosphate-dehydrogenase; GLS1, glutaminase; GPNA, gamma-L-glutamyl-p-nitroanilide; GSH, glutathione; GSSG, glutathione disulfide; HADH, hydroxylacyl-CoA dehydrogenase; HCC, hepatocellular carcinoma; HIF, hypoxia inducible factors; HK, hexokinase; H-Ser(Bzl), OH benzylserine; IDH1, isocitrate dehydrogenase; L2HGDH, 2-HG dehydrogenase; LDH, lactate dehydrogenase; L-DON, 6-diazo-5-oxo-L-norleucine; LND, lonidamine; MCAD, medium-chain acyl-coA dehydrogenase; MCT, monocarboxylate transporters 1 and 4; MTD, maximum tolerable dose; NHI, N-hydroxyindole-2-carboxylates; OGDH, α -ketoglutarate dehydrogenase, oxoglutarate dehydrogenase; PDH, pyruvate dehydrogenase; PDK, pyruvate dehydrogenase kinase; PEG-ADI, pegylated arginine deiminase; PEP, phosphoenolpyruvic acid; PFK, phosphofructokinase; PGAM1, phosphoglycerate mutase; PGK1,

phosphoglycerate kinase; PKM2, pyruvate kinase; PPP, pentose phosphate pathway; RTK, receptor tyrosine kinase; SCEH, short-chain enoyl-coA hydratase; SDHB, succinate dehydrogenase; TCA, tricarboxylic acid; TCGA, The Cancer Genome Atlas; TKT, transketolase; TOFA, 5-(tetradecyloxy)-2-furoic acid; VLCAD, very long chain acyl-coenzyme A dehydrogenase

Acknowledgements

We kindly thank "het Scholten-Cordes fonds," "het Prins Bernard Cultuur fonds," "de Saal van Zwaneberg stichting," "de René Vogels Stichting," and "de Fundatie van de Vrijvrouw van Renswoude" for providing financial support to JvdM.

Funding

Financial support for this study was provided by "het Scholten-Cordes fonds," "het Prins Bernard Cultuur fonds," "de Saal van Zwaneberg stichting," "de Rene Vogels Stichting," and "de Fundatie van de Vrijvrouw van Renswoude" (to J.v.d.M.)

Availability of data and materials

Not applicable.

Authors' contributions

JvdM, DJP, AKG, and JWM conceived the study and contributed to the design. JvdM, HMV, and JWM drafted and revised the manuscript. All authors read, approved, and agreed to be accountable for all aspects of the manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Author details

¹Department of Hematology/Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Ave, Boston, MA 02215, USA. ²Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. ³Department of Internal Medicine, OLVG, Jan van Tooropstraat 164, 1061 AE Amsterdam, The Netherlands.

Received: 28 March 2016 Accepted: 30 June 2016

Published online: 13 July 2016

References

- Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. *Cancer Treat Rev*. 2008;34(3):193–205.
- Chow WH, Devesa SS, Warren JL, Fraumeni Jr JF. Rising incidence of renal cell cancer in the United States. *JAMA*. 1999;281(17):1628–31.
- Patarid JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. *J Clin Oncol*. 2005;23(12):2763–71.
- Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature*. 2013;499(7456):43–9.
- Gatto F, Nookaew I, Nielsen J. Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell renal carcinoma. *Proc Natl Acad Sci U S A*. 2014;111(9):E866–75.
- Warburg O. On the origin of cancer cells. *Science*. 1956;123(3191):309–14.
- Qiu B, Ackerman D, Sanchez DJ, Li B, Ochocki JD, Grazioli A, et al. HIF2alpha-dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma. *Cancer Discov*. 2015;5(6):652–67.
- Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH, Kim JH, et al. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. *Int J Cancer*. 2007;120(4):897–905.
- Zhou W, Simpson PJ, McFadden JM, Townsend CA, Medghalchi SM, Vadlamudi A, et al. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. *Cancer Res*. 2003;63(21):7330–7.
- Sato Y, Yoshizato T, Shiraiishi Y, Maekawa S, Okuno Y, Kamura T, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. *Nat Genet*. 2013;45(8):860–7.
- Girgis H, Masui O, White NM, Scorilas A, Rotondo F, Seiwright A, et al. Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. *Mol Cancer*. 2014;13(101):4598–13.
- White-AI Habeeb NM, Di Meo A, Scorilas A, Rotondo F, Masui O, Seiwright A, et al. Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma. *Clin Exp Metastasis*. 2015;32(6):531–41.
- Kim Y, Choi JW, Lee JH, Kim YS. Expression of lactate/H(+) symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses. *Hum Pathol*. 2015;46(1):104–12.
- Fisel P, Kruck S, Winter S, Bedke J, Hennenlotter J, Nies AT, et al. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome. *Clin Cancer Res*. 2013;19(18):5170–81.
- Perroud B, Ishimaru T, Borowsky AD, Weiss RH. Grade-dependent proteomics characterization of kidney cancer. *Mol Cell Proteomics*. 2009;8(5):971–85.
- Wettersten HI, Hakimi AA, Morin D, Bianchi C, Johnstone ME, Donohoe DR, et al. Grade-dependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis. *Cancer Res*. 2015;75(12):2541–52.
- Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A, et al. An integrated metabolic atlas of clear cell renal cell carcinoma. *Cancer Cell*. 2016;29(1):104–16.
- Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. *Nat Rev Drug Discov*. 2013;12(12):931–47.
- Moore LE, Jaeger E, Nickerson ML, Brennan P, De Vries S, Roy R, et al. Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation. *Oncogenesis*. 2012;1, e14.
- Gordan JD, Lal P, Dondeti VR, Parekh KN, Oquendo CE, et al. HIF-1alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. *Cancer Cell*. 2008;14(6):435–46.
- Schonenberger D, Harlander S, Rajski M, Jacobs RA, Lundby AK, Adlesic M, et al. Formation of renal cysts and tumors in Vhl/Trp53-deficient mice requires HIF-1alpha and HIF-2alpha. *Cancer Res*. 2016;12.
- LaGory EL, Wu C, Taniguchi CM, Ding CK, Chi JT, Von Eyben R, et al. Suppression of PGC-1alpha is critical for reprogramming oxidative metabolism in renal cell carcinoma. *Cell Rep*. 2015;12(1):116–27.
- Shen C, Beroukhi R, Schumacher SE, Zhou J, Chang M, Signoretti S, et al. Genetic and functional studies implicate HIF1alpha as a 14q kidney cancer suppressor gene. *Cancer Discov*. 2011;1(3):222–35.
- Rankin EB, Tomaszewski JE, Haase VH. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. *Cancer Res*. 2006;66(5):2576–83.
- Li B, Qiu B, Lee DS, Walton ZE, Ochocki JD, Mathew LK, et al. Fructose-1,6-bisphosphatase opposes renal carcinoma progression. *Nature*. 2014; 513(7517):251–5.
- Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. *Nature*. 2011;481(7381):385–8.
- Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. *Nature*. 2011;481(7381):380–4.
- Shroff EH, Eberlin LS, Dang VM, Gouw AM, Gabay M, Adam SJ, et al. MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. *Proc Natl Acad Sci U S A*. 2015;112(21):6539–44.
- Gameiro PA, Yang J, Metelo AM, Perez-Carro R, Baker R, Wang Z, et al. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. *Cell Metab*. 2013; 17(3):372–85.
- Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. *Cancer Cell*. 2007;11(4):335–47.
- Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. *Mol Cell*. 2010;39(2):171–83.
- Dibble CC, Cantley LC. Regulation of mTORC1 by PI3K signaling. *Trends Cell Biol*. 2015;25(9):545–55.
- Edinger AL, Thompson CB. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. *Mol Biol Cell*. 2002;13(7):2276–88.

34. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. *Genes Dev.* 2001;15(11):1406–18.
35. Deprez J, Vertommen D, Alessi DR, Hue L, Rider MH. Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. *J Biol Chem.* 1997;272(28):17269–75.
36. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, et al. Akt stimulates aerobic glycolysis in cancer cells. *Cancer Res.* 2004;64(11):3892–9.
37. Buzzai M, Bauer DE, Jones RG, DeBerardinis RJ, Hatzivassiliou G, Elstrom RL, et al. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. *Oncogene.* 2005;24(26):4165–73.
38. Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A, et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. *Sci Transl Med.* 2011;3(94):94ra70.
39. Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. *Mol Cancer Ther.* 2012;11(8):1672–82.
40. Chen Z, Zhang H, Lu W, Huang P. Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate. *Biochim Biophys Acta.* 2009;1787(5):553–60.
41. Birsoy K, Wang T, Possemato R, Yilmaz OH, Koch CE, Chen WW, et al. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. *Nat Genet.* 2013;45(1):104–8.
42. Nilsson H, Lindgren D, Mandahl Forsberg A, Mulder H, Axelsson H, Johansson ME. Primary clear cell renal carcinoma cells display minimal mitochondrial respiratory capacity resulting in pronounced sensitivity to glycolytic inhibition by 3-Bromopyruvate. *Cell Death Dis.* 2015;6, e1585.
43. Ben-Horin H, Tassinari M, Vivi A, Navon G, Kaplan O. Mechanism of action of the antineoplastic drug lonidamine: 31P and 13C nuclear magnetic resonance studies. *Cancer Res.* 1995;55(13):2814–21.
44. Davidescu M, Macchioni L, Scaramozzino G, Cristina Marchetti M, Migliorati G, Vitale R, et al. The energy blockers bromopyruvate and lonidamine lead GL15 glioblastoma cells to death by different p53-dependent routes. *Sci Rep.* 2015;5:14343.
45. Xu IM, Lai RK, Lin SH, Tse AP, Chiu DK, Koh HY, et al. Transketolase counteracts oxidative stress to drive cancer development. *Proc Natl Acad Sci U S A.* 2016;113(6):E725–34.
46. Lucarelli G, Galleggiante V, Rutigliano M, Sanguedolce F, Cagiano S, Bufo P, et al. Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. *Oncotarget.* 2015;6(15):13371–86.
47. Preuss J, Richardson AD, Pinkerton A, Hedrick M, Sergienko E, Rahlfs S, et al. Identification and characterization of novel human glucose-6-phosphate dehydrogenase inhibitors. *J Biomol Screen.* 2013;18(3):286–97.
48. Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M, et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. *Nat Cell Biol.* 2011;13(3):310–6.
49. Panka DJ, Liu Q, Geissler AK, Mier JW. Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells. *Mol Cancer.* 2013;12(17):4598–12.
50. Boros LG, Puigjaner J, Cascante M, Lee WN, Brandes JL, Bassilian S, et al. Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. *Cancer Res.* 1997;57(19):4242–8.
51. Thomas AA, Le Huerou Y, De Meese J, Gunawardana I, Kaplan T, Romoff TT, et al. Synthesis, in vitro and in vivo activity of thiamine antagonist transketolase inhibitors. *Bioorg Med Chem Lett.* 2008;18(6):2206–10.
52. Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. *Mol Cancer Ther.* 2008;7(1):110–20.
53. Clem BF, O'Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr II DA, et al. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. *Mol Cancer Ther.* 2013;12(8):1461–70.
54. Jung DW, Kim WH, Park SH, Lee J, Kim J, Su D, et al. A unique small molecule inhibitor of enolase clarifies its role in fundamental biological processes. *ACS Chem Biol.* 2013;8(6):1271–82.
55. Tan B, Young DA, Lu ZH, Wang T, Meier TI, Shepard RL, et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications. *J Biol Chem.* 2013;288(5):3500–11.
56. Hitosugi T, Zhou L, Elf S, Fan J, Kang HB, Seo JH, et al. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. *Cancer Cell.* 2012;22(5):585–600.
57. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. *Nature.* 2008;452(7184):230–3.
58. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. *Nature.* 2008;452(7184):181–6.
59. Hosios AM, Fiske BP, Gui DY, Vander Heiden MG. Lack of evidence for PKM2 protein kinase activity. *Mol Cell.* 2015;59(5):850–7.
60. Vander Heiden MG, Christofk HR, Schuman E, Subtelny AO, Sharfi H, Harlow EE, et al. Identification of small molecule inhibitors of pyruvate kinase M2. *Biochem Pharmacol.* 2010;79(8):1118–24.
61. Kung C, Hixon J, Choe S, Marks K, Gross S, Murphy E, et al. Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. *Chem Biol.* 2012;19(9):1187–98.
62. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. *Cell Metab.* 2006;3(3):187–97.
63. Kinnaird A, Dromparis P, Saleme B, Gurtu V, Watson K, Paulin R, et al. Metabolic modulation of clear-cell renal cell carcinoma with dichloroacetate, an inhibitor of pyruvate dehydrogenase kinase. *Eur Urol.* 2015;30.
64. Kato M, Li J, Chuang JL, Chuang DT. Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol. *Structure.* 2007;15(8):992–1004.
65. Moore JD, Staniszewska A, Shaw T, D'Alessandro J, Davis B, Surgenor A, et al. VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context-dependent cytoskeleton in cancer cells. *Oncotarget.* 2014;5(24):12862–76.
66. Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, Linehan WM, et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. *Mol Cancer Ther.* 2009;8(3):626–35.
67. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. *Proc Natl Acad Sci U S A.* 2010;107(5):2037–42.
68. Yang Y, Su D, Zhao L, Zhang D, Xu J, Wan J, et al. Different effects of LDH-A inhibition by oxamate in non-small cell lung cancer cells. *Oncotarget.* 2014;5(23):11886–96.
69. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. *Nature.* 2014;510(7506):542–6.
70. Liu J, Li M, Song B, Jia C, Zhang L, Bai X, et al. Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. *Urol Oncol.* 2013;31(2):264–70.
71. Yang J, Kalogerou M, Gallacher J, Sampson JR, Shen MH. Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin. *Eur J Cancer.* 2013;49(6):1479–90.
72. Gerlinger M, Santos CR, Spencer-Dene B, Martinez P, Endesfelder D, Burrell RA, et al. Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. *J Pathol.* 2012;227(2):146–56.
73. Polanski R, Hodgkinson CL, Fusi A, Nonaka D, Priest L, Kelly P, et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. *Clin Cancer Res.* 2014;20(4):926–37.
74. Hanson DJ, Nakamura S, Amachi R, Hiasa M, Oda A, Tsuji D, et al. Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation. *Oncotarget.* 2015;6(32):33568–86.
75. Le Floch R, Chiche J, Marchiq I, Naiken T, Ilc K, Murray CM, et al. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. *Proc Natl Acad Sci U S A.* 2011;108(40):16663–8.
76. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. *Proc Natl Acad Sci U S A.* 2007;104(49):19345–50.

77. Rabinovich S, Adler L, Yizhak K, Sarver A, Silberman A, Agron S, et al. Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis. *Nature*. 2015;527(7578):379–83.
78. Ensor CM, Holsberg FW, Bomalaski JS, Clark MA. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. *Cancer Res*. 2002;62(19):5443–50.
79. Fletcher M, Ramirez ME, Sierra RA, Raber P, Thevenot P, Al-Khami AA, et al. L-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. *Cancer Res*. 2015;75(2):275–83.
80. Betsunoh H, Fukuda T, Anzai N, Nishihara D, Mizuno T, Yuki H, et al. Increased expression of system large amino acid transporter (LAT)-1 mRNA is associated with invasive potential and unfavorable prognosis of human clear cell renal cell carcinoma. *BMC Cancer*. 2013;13(509):2407–13.
81. Oda K, Hosoda N, Endo H, Saito K, Tsuchihara K, Yamamura M, et al. L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. *Cancer Sci*. 2010;101(1):173–9.
82. Lob S, Konigsrainer A, Zieker D, Brucher BL, Rammensee HG, Opelz G, et al. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. *Cancer Immunol Immunother*. 2009;58(1):153–7.
83. Ganti S, Taylor SL, Abu About O, Yang J, Evans C, Osier MV, et al. Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. *Cancer Res*. 2012;72(14):3471–9.
84. Koblish HK, Hansbury MJ, Bowman KJ, Yang G, Neilan CL, Haley PJ, et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. *Mol Cancer Ther*. 2010;9(2):489–98.
85. Lyons SD, Sant ME, Christopherson RI. Cytotoxic mechanisms of glutamine antagonists in mouse L1210 leukemia. *J Biol Chem*. 1990;265(19):11377–81.
86. Hassanein M, Qian J, Hoeksema MD, Wang J, Jacobovitz M, Ji X, et al. Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer. *Int J Cancer*. 2015;137(7):1587–97.
87. Wang Q, Hardie RA, Hoy AJ, Van Geldermalsen M, Gao D, Fazli L, et al. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. *J Pathol*. 2015;236(3):278–89.
88. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. *Cancer Res*. 2010;70(22):8981–7.
89. Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. *Mol Cancer Ther*. 2014;13(4):890–901.
90. Yang C, Ko B, Hensley CT, Jiang L, Wasti AT, Kim J, et al. Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. *Mol Cell*. 2014;56(3):414–24.
91. Qing G, Li B, Vu A, Skuli N, Walton ZE, Liu X, et al. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. *Cancer Cell*. 2012;22(5):631–44.
92. Rej R. Aminoxyacetate is not an adequate differential inhibitor of aspartate aminotransferase isoenzymes. *Clin Chem*. 1977;23(8):1508–9.
93. Moreadith RW, Lehninger AL. The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)⁺-dependent malic enzyme. *J Biol Chem*. 1984;259(10):6215–21.
94. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. *Proc Natl Acad Sci U S A*. 2008;105(48):18782–7.
95. Wise DR, Ward PS, Shay JE, Cross JR, Gruber JJ, Sachdeva UM, et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. *Proc Natl Acad Sci U S A*. 2011;108(49):19611–6.
96. Yoo H, Antoniewicz MR, Stephanopoulos G, Kelleher JK. Quantifying reductive carboxylation flux of glutamine to lipid in a brown adipocyte cell line. *J Biol Chem*. 2008;283(30):20621–7.
97. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. *Science*. 2013;340(6132):626–30.
98. Shim EH, Livi CB, Rakheja D, Tan J, Benson D, Parekh V, et al. L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. *Cancer Discov*. 2014;4(11):1290–8.
99. Zaidi N, Royaux I, Swinnen JV, Smans K. ATP citrate lyase knockdown induces growth arrest and apoptosis through different cell- and environment-dependent mechanisms. *Mol Cancer Ther*. 2012;11(9):1925–35.
100. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, et al. ATP citrate lyase inhibition can suppress tumor cell growth. *Cancer Cell*. 2005;8(4):311–21.
101. Beckers A, Organe S, Timmermans L, Scheys K, Peeters A, Brusselmans K, et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. *Cancer Res*. 2007;67(17):8180–7.
102. Harwood Jr HJ, Petras SF, Shelly LD, Zaccaro LM, Perry DA, Makowski MR, et al. Isozyme-nonspecific N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. *J Biol Chem*. 2003;278(39):37099–111.
103. Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot GL, et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. *Cancer Res*. 2000;60(2):213–8.
104. Horiguchi A, Asano T, Asano T, Ito K, Sumitomo M, Hayakawa M. Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells. *J Urol*. 2008;180(2):729–36.
105. Sadowski MC, Pouwer RH, Gunter JH, Lubik AA, Quinn RJ, Nelson CC. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer. *Oncotarget*. 2014;5(19):9362–81.
106. Vazquez MJ, Leavens W, Liu R, Rodriguez B, Read M, Richards S, et al. Discovery of GSK837149A, an inhibitor of human fatty acid synthase targeting the beta-ketoacyl reductase reaction. *FEBS J*. 2008;275(7):1556–67.
107. Veigel D, Wagner R, Stubiger G, Wuczkowski M, Filipits M, Horvat R, et al. Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells. *Int J Cancer*. 2015;136(9):2078–90.
108. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, et al. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BE225 compared with rapamycin in renal cell carcinoma. *Clin Cancer Res*. 2010;16(14):3628–38.
109. Lin A, Piao HL, Zhuang L, Dos Sarbassov D, Ma L, Gan B. FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway. *Cancer Res*. 2014;74(6):1682–93.
110. Yamada T, Horinaka M, Shinnoh M, Yoshioka T, Miki T, Sakai T. A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma. *Int J Oncol*. 2013;43(4):1080–6.
111. Elfiky AA, Aziz SA, Conrad PJ, Siddiqui S, Hackl W, Maira M, et al. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. *J Transl Med*. 2011;9(133):5876–9.
112. Joshi S, Singh AR, Durden DL. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma. *Cancer Chemother Pharmacol*. 2015;75(3):595–608.
113. Holland WS, Tepper CG, Pietri JE, Chinn DC, Gandara DR, Mack PC, et al. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. *Cancer Chemother Pharmacol*. 2012;69(1):185–94.
114. Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. *Cancer Res*. 2010;70(2):621–31.
115. Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. *Cancer Res*. 2009;69(15):6232–40.
116. Jalota-Badhwar A, Bhatia DR, Boreddy S, Joshi A, Venkatraman M, Desai N, et al. P7170: a novel molecule with unique profile of mTORC1/C2 and activin receptor-like kinase 1 inhibition leading to antitumor and antiangiogenic activity. *Mol Cancer Ther*. 2015;14(5):1095–106.
117. Jiang Q, Weiss JM, Back T, Chan T, Ortaldo JR, Guichard S, et al. mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. *Cancer Res*. 2011;71(12):4074–84.
118. Stein M, Lin H, Jeyamohan C, Dvorzhinski D, Gounder M, Bray K, et al. Targeting tumor metabolism with 2-deoxyglucose in patients with

- castrate-resistant prostate cancer and advanced malignancies. *Prostate*. 2010;70(13):1388–94.
119. Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, et al. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2013;71(2):523–30.
120. Yamasaki T, Tran TA, Oz OK, Raj GV, Schwarz RE, Deberardinis RJ, et al. Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC. *Nat Rev Urol*. 2011;8(3):165–71.
121. Band PR, Deschamps M, Besner JG, Leclaire R, Gervais P, De Sanctis A. Phase I toxicologic study of lonidamine in cancer patients. *Oncology*. 1984;41 Suppl 1:56–9.
122. Young CW, Currie VE, Kim JH, O'Hehir MA, Farag FM, Kinahan JE. Phase I and clinical pharmacologic evaluation of lonidamine in patients with advanced cancer. *Oncology*. 1984;41 Suppl 1:60–5.
123. Robins HI, Longo WL, Lagoni RK, Neville AJ, Hugander A, Schmitt CL, et al. Phase I trial of lonidamine with whole body hyperthermia in advanced cancer. *Cancer Res*. 1988;48(22):6587–92.
124. Stahl M, Schmoll E, Becker H, Schlichter A, Hoffmann L, Wagner H, et al. Lonidamine versus high-dose tamoxifen in progressive, advanced renal cell carcinoma: results of an ongoing randomized phase II study. *Semin Oncol*. 1991;18(2 Suppl 4):33–7.
125. Weinerman BH, Eisenhauer EA, Besner JG, Coppin CM, Stewart D, Band PR. Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study. *Cancer Treat Rep*. 1986;70(6):751–4.
126. Chu QS, Sangha R, Spratlin J, J Vos L, Mackey JR, McEwan AJ, et al. A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors. *Invest New Drugs*. 2015;33(3):603–10.
127. Dunbar EM, Coats BS, Shroads AL, Langaee T, Lew A, Forder JR, et al. Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. *Invest New Drugs*. 2014;32(3):452–64.
128. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, et al. Metabolic modulation of glioblastoma with dichloroacetate. *Sci Transl Med*. 2010;2(31):31ra34.
129. Laurie SA, Miller VA, Grant SC, Kris MG, Ng KK. Phase I study of green tea extract in patients with advanced lung cancer. *Cancer Chemother Pharmacol*. 2005;55(1):33–8.
130. Shanafelt TD, Call TG, Zent CS, LaPlant B, Bowen DA, Roos M, et al. Phase I trial of daily oral polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. *J Clin Oncol*. 2009;27(23):3808–14.
131. Chow HH, Hakim IA, Vining DR, Crowell JA, Ranger-Moore J, Chew WM, et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. *Clin Cancer Res*. 2005;11(12):4627–33.
132. Cheng JJ, Li H, Tan HS, Tan PH, Ng LG, Ng QS, et al. Metformin use in relation with survival outcomes of patients with renal cell carcinoma. *Clin Genitourin Cancer*. 2016;14(2):168–75.
133. Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bartschi D, et al. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). *Eur Urol*. 2014; 66(3):468–74.
134. Kordes S, Pollak MN, Zwiderman AH, Mathot RA, Weterman MJ, Beeker A, et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. *Lancet Oncol*. 2015; 16(7):839–47.
135. Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. *Clin Cancer Res*. 2009;15(9):3172–6.
136. Hoen K, Saltz LB, Hollywood E, Burk K, Hanauske AR. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. *Invest New Drugs*. 2008;26(1):45–51.
137. Ott PA, Carvajal RD, Pandit-Taskar N, Jungbluth AA, Hoffman EW, Wu BW, et al. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. *Invest New Drugs*. 2013;31(2):425–34.
138. Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, et al. A Phase I study of indoximod in patients with advanced malignancies. *Oncotarget*. 2016 Mar 20.
139. Rahman A, Smith FP, Luc PT, Woolley PV. Phase I study and clinical pharmacology of 6-diazo-5-oxo-L-norleucine (DON). *Invest New Drugs*. 1985;3(4):369–74.
140. McGovern JP, Pratt EA, Belt RJ, Taylor SA, Benjamin RS, Ardalan B, et al. Pharmacokinetic and biochemical studies on acivicin in phase I clinical trials. *Cancer Res*. 1985;45(9):4460–3.
141. Weiss GR, McGovern JP, Schade D, Kufe DW. Phase I and pharmacological study of acivicin by 24-hour continuous infusion. *Cancer Res*. 1982;42(9):3892–5.
142. Hidalgo M, Rodriguez G, Kuhn JG, Brown T, Weiss G, MacGovern JP, et al. A phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies. *Clin Cancer Res*. 1998;4(11):2763–70.
143. Elson PJ, Kvols LK, Vogl SE, Glover DJ, Hahn RG, Trump DL, et al. Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiazazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma. *Invest New Drugs*. 1988;6(2):97–103.
144. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. *JAMA*. 2005;293(23):2873–83.
145. Zhi J, Melia AT, Eggers H, Joly R, Patel IH. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. *J Clin Pharmacol*. 1995;35(11):1103–8.
146. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. *Nat Rev Clin Oncol*. 2013;10(3):143–53.
147. Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. *Clin Cancer Res*. 2015;21(1):77–86.
148. Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Brana I, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. *Clin Cancer Res*. 2014;20(1):233–45.
149. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. *Clin Cancer Res*. 2012;18(15):4173–82.
150. Mahadevan D, Chiorean EG, Harris WB, Von Hoff DD, Stejskal-Barnett A, Qi W, et al. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. *Eur J Cancer*. 2012; 48(18):3319–27.
151. Gopal AK, Kahl BS, De Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. *N Engl J Med*. 2014;370(11):1008–18.
152. Wee S, Wiederschain D, Maira SM, Loo A, Miller C, DeBeaumont R, et al. PTEN-deficient cancers depend on PIK3CB. *Proc Natl Acad Sci U S A*. 2008; 105(35):13057–62.
153. Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, et al. Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. *Mol Cancer Ther*. 2014;13(5):1117–29.
154. Yap TA, Yan L, Patnaik A, Fearon I, Olmos D, Papadopoulos K, et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. *J Clin Oncol*. 2011;29(35):4688–95.
155. Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, Kolesar J, et al. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. *Clin Cancer Res*. 2004; 10(22):7450–6.
156. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. *Cancer Cell*. 2009;16(1):21–32.
157. Bodnar L, Stec R, Cierniak S, Synowiec A, Wcislo G, Jesiotr M, et al. Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines. *Ann Oncol*. 2015;26(7):1385–9.
158. Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. *J Clin Oncol*. 2012;30(27):3402–7.
159. Bendell JC, Kurkjian C, Infante JR, Bauer TM, Burris III HA, Greco FA, et al. A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors. *Invest New Drugs*. 2015;33(2):463–71.

160. Papadopoulos KP, Tabernero J, Markman B, Patnaik A, Tolcher AW, Baselga J, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. *Clin Cancer Res.* 2014;20(9):2445–56.
161. Naing A, Aghajanian C, Raymond E, Olmos D, Schwartz G, Oelmann E, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. *Br J Cancer.* 2012;107(7):1093–9.
162. Basu B, Dean E, Puglisi M, Greystoke A, Ong M, Burke W, et al. First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014. *Clin Cancer Res.* 2015;21(15):3412–9.
163. Powles T, Wheeler M, Din O, Geldart T, Boleti E, Stockdale A, et al. A randomised phase 2 study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer. *Eur Urol.* 2015;10.
164. Sounni NE, Cimino J, Blacher S, Primac I, Truong A, Mazzucchelli G, et al. Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. *Cell Metab.* 2014;20(2):280–94.
165. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. *Proc Natl Acad Sci U S A.* 2011;108(9):3749–54.
166. Kumar K, Wigfield S, Gee HE, Devlin CM, Singleton D, Li JL, et al. Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. *J Mol Med (Berl).* 2013;91(6):749–58.
167. Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, et al. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. *Clin Cancer Res.* 2011;17(18):6021–8.
168. Makhov PB, Golovine K, Kutikov A, Teper E, Canter DJ, Simhan J, et al. Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. *Mol Cancer Ther.* 2012;11(7):1510–7.
169. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. *J Clin Invest.* 2008;118(9):3065–74.
170. Mahalingam D, Medina EC, Esquivel II JA, Espitia CM, Smith S, Oberheu K, et al. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. *Clin Cancer Res.* 2010;16(1):141–53.
171. Voss MH, Hakimi AA, Pham CG, Brannon AR, Chen YB, Cunha LF, et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. *Clin Cancer Res.* 2014;20(7):1955–64.
172. Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy. *Nat Rev Clin Oncol.* 2011;8(9):528–39.
173. Palm W, Park Y, Wright K, Pavlova NN, Tuveson DA, Thompson CB. The utilization of extracellular proteins as nutrients is suppressed by mTORC1. *Cell.* 2015;162(2):259–70.
174. Rosich L, Xargay-Torrent S, Lopez-Guerra M, Campo E, Colomer D, Roue G. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma. *Clin Cancer Res.* 2012;18(19):5278–89.
175. Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Satoh N, et al. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. *J Clin Invest.* 2015;125(4):1591–602.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

